Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101659. doi: 10.1016/j.berh.2021.101659. Epub 2021 Jan 13.
Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-α) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants.
几种免疫抑制疗法已被研究作为严重和危重新冠病毒病 2019（COVID-19）患者的潜在治疗方法。值得注意的例子包括皮质类固醇、白细胞介素 6（IL-6）、白细胞介素 1（IL-1）、Janus 激酶（JAK）和肿瘤坏死因子-α（TNF-α）抑制剂。本叙述性综述的目的是分析这些选定的抗风湿药物治疗 COVID-19 的机制合理性和现有证据。目前，只有皮质类固醇已被证明能有效降低死亡率，并在治疗严重和危重新冠病毒病的临床指南中推荐使用。多项随机对照试验（RCT）正在进行中，以确定其他免疫抑制剂的作用。
